皮下注射抗IL-17A/F纳米抗体M1095多剂量递增治疗中重度银屑病的随机双盲安慰剂对照1期研究
这项多中心、双盲、安慰剂对照的剂量递增1期研究将44例中重度斑块状银屑病患者按4:1随机分配接受皮下M1095(30、60、120或240 mg)或安慰剂,每两周一次共6周。M1095总体安全性良好,最常见不良事件为瘙痒和头痛,终末半衰期为11至12天,暴露呈剂量比例关系;240 mg组至第85天时100%和56%的患者分别达到PASI 90和PASI 100。
要点
- M1095皮下注射安全性良好,最常见不良事件为瘙痒(n=4)和头痛(n=3)。
- 终末半衰期为11至12天,AUC和Cmax呈剂量比例关系。
- 240 mg组至第85天PASI 90和PASI 100应答率分别为100%和56%。
核心结论
- 多剂皮下M1095安全性良好,并呈剂量依赖性改善银屑病。
研究设计与样本
- 多中心、双盲、安慰剂对照剂量递增1期研究,44例中重度斑块状银屑病患者按4:1随机接受皮下M1095(30、60、120或240 mg)或安慰剂,每两周一次共6周,分4个递增剂量队列。
主要发现
- M1095最常见治疗中出现的不良事件为瘙痒(n=4)和头痛(n=3),2例因不良事件退出(注射部位反应和肝酶升高)。
- M1095终末半衰期为11至12天,AUC和最大浓度呈剂量比例关系。
- 10例M1095治疗患者抗药抗体阳性,其中5例出现治疗中出现的抗药抗体反应,对M1095暴露无影响。
- M1095治疗观察到银屑病炎症标志物显著下降。
- 至第85天,接受M1095 240 mg的患者中100%和56%分别达到PASI 90和PASI 100,静态医师全面评估和受累体表面积也有改善。
关键数值与推荐
- 至第85天,M1095 240 mg组PASI 90应答率为100%,PASI 100应答率为56%。
- M1095终末半衰期为11至12天。
临床怎么用
- M1095多剂皮下给药在中重度斑块状银屑病中显示良好安全性及剂量依赖性疗效,支持后续临床开发。
局限性
- 疗效数据解释受样本量小限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interleukin 17 is involved in the pathogenesis of psoriasis, a chronic debilitating disease. OBJECTIVES: To evaluate the safety/tolerability, immunogenicity, pharmacokinetics/pharmacodynamics, and efficacy of M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe plaque psoriasis. METHODS: This multicenter, double-blind, placebo-controlled dose escalation phase 1 study randomized 44 patients 4:1 to treatment with subcutaneous M1095 (30, 60, 120, or 240 mg) or placebo biweekly for 6 weeks, in 4 ascending dose cohorts. RESULTS: The most frequent treatment-emergent adverse events with M1095 were pruritus (n = 4) and headache (n = 3); 2 patients withdrew owing to adverse events (injection site reaction and elevated liver enzyme levels). The terminal half-life of M1095 was 11 to 12 days. The area under the curve/maximum concentration was dose proportional. Of 10 M1095-treated patients positive for antidrug antibodies, 5 showed treatment-emergent antidrug antibody responses. There was no effect on M1095 exposure. Marked decreases in psoriasis inflammatory markers were observed with M1095. By day 85, 100% and 56% of patients receiving M1095, 240 mg, achieved psoriasis area and severity index 90 and 100, respectively. Improvements in static Physician's Global Assessment and affected body surface area were also seen. LIMITATIONS: Interpretation of efficacy data is limited by the small sample size. CONCLUSION: Multiple subcutaneous doses of M1095 showed a favorable safety profile with dose-dependent improvements in psoriasis.
引用
- Svecova D, Lubell MW, Casset-Semanaz F, et al. A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasis. J Am Acad Dermatol. 2019. PMID: 30926369. doi:10.1016/j.jaad.2019.03.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。